Pharmafile Logo
Pharmafocus logo
Advanced Search

Humira

Showing 15 posts of 90 posts found.

novartis_side_building

Novartis to compare Cosentyx with Humira in new clinical trials

June 8, 2016
Research and Development Cosentyx, Humira, Novartis, comparison, eular 2016

Novartis has announced that it plans to directly compare Cosentyx (secukinumab) versus Humira (adalimumab) in patients with ankylosing spondylitis and …

News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …

News
sanofi_logo_on_building

Sanofi says its RA drug bested Humira in Phase III study

March 11, 2016
Medical Communications, Research and Development Humira, Regeneron, Sanofi

Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …

News
humira_abbott_

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016
Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …

Feature
merck_innovation_centre

Merck begins late-stage trials of Humira biosimilar

March 2, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars

Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …

News
abbvie

AbbVie posts strong Q4 results

February 1, 2016
Sales and Marketing AbbVie, Humira, Viekira Pak

AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing …

News

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

News
amgen_flag

Amgen’s Humira biosimilar succeeds in Phase III arthritis study

November 16, 2015
Research and Development, Sales and Marketing Amgen, Humira

Amgen says its Humira (adalimumab) biosimilar candidate ABP 501 proved its clinical equivalence to Abbvie’s blockbuster drug in a head-to-head …

News

Lilly/Incyte RA drug bests Humira in Phase III trial

November 10, 2015
Research and Development Humira, baricitinib, lilly, phase III, rheumatoid arthritis

Eli Lilly says its investigational therapy baricitinib outperformed AbbVie’s Humira after 12 weeks in a late-stage study of people with …

News
abbvie_0

AbbVie reports 26% rise in Q3 revenues

October 30, 2015
Sales and Marketing AbbVie, Humira

AbbVie has announced stronger-than-anticipated Q3 financial results, its revenues increasing 26.2% on the same period last year to $5.944 billion, …

News
Humira

AbbVie’s Humira receives first European OK for skin condition

August 3, 2015
Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab

The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …

News
Humira image

AbbVie’s Humira meets endpoint in eye disease study

May 6, 2015
Research and Development, Sales and Marketing AbbVie, FDA, Humira, Zydus Cadila, adalimumab, uveitis

In a Phase III trial AbbVie’s anti-inflammatory medicine Humira has been shown to significantly lower the risk of uncontrolled uveitis …

News
Abbbie image

AbbVie buys Pharmacyclics in $21 billion deal

March 5, 2015
Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica

AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …

News

NICE recommends hep C and bowel treatments

February 26, 2015
Sales and Marketing AbbVie, Humira, J&J, JJ, Janssen, Merck, Remicade, Simponi, olysio

Three drugs to treat chronic bowel condition ulcerative colitis and one for hepatitis C will be funded by the NHS …

News
Hospira image

Pfizer to buy Hospira for $17 billion

February 5, 2015
Sales and Marketing Hospira, Humira, Pfizer, acquisition, biosimilars, merger

Pfizer has struck a deal with Hospira to acquire the company in a deal worth around $17 billion. Industry analysts …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024